13 results about "Combining vaccines" patented technology

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

The invention discloses a modular combined vaccine soluble microneedle patch based on a mechanical interlocking tenon-and-mortise structure as well as a preparation method and application of the modular combined vaccine soluble microneedle patch. According to the combined and spliced micro-needle vaccine patch designed by the invention, synchronous delivery of various vaccines is realized by virtue of a micro-needle technology through fragmented loading and mechanical interlocking'mortise and tenon 'structural design, mutual interference among different vaccines is reduced at the same time, efficient protection can be provided for groups needing multi-vaccine protection by virtue of one-time inoculation, the number of inoculants is reduced, and the immune procedure is simplified; vaccine hesitation is reduced, and inoculation rate is increased; meanwhile, the biosoluble material of the microneedle structure can quickly release antigens in the skin to stimulate immune cells to aggregate so as to enhance the immune effect; the micron-sized needle array (lt; 500 m) acts on the superficial layer of the skin, is painless and can be designed into a self-adhesive patch, so that the inoculation compliance is improved; single-dose inoculation can also reduce medical cost, is suitable for resource-deficient regions, improves accessibility and burdenability, and accelerates establishment of a population immune barrier.

The application discloses a competitive ELISA detection method for Hib polysaccharide in an aluminum-containing adjuvant vaccine, and specifically, the method comprises the following steps: enzyme label plate preparation: coating Hib stock solution or PRP derivative on an enzyme label plate to prepare an enzyme label plate required for ELISA reaction; aluminum adsorption Hib sample treatment: blocking aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples with BSA, respectively, and then diluting the aluminum adjuvant adsorbed Hib reference and aluminum adjuvant combined vaccine samples after blocking; ELISA detection: adding the diluted aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples into the enzyme label plate, respectively, and then adding Hib specific antibody, generating ELISA signals through enzyme label antibody catalysis of substrates, establishing a mathematical relationship between absorbance and Hib polysaccharide content, and quantitatively calculating the Hib polysaccharide content in the aluminum adjuvant containing vaccine sample.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The application discloses an influenza virus universal and coronavirus combined polypeptide and application of a vaccine thereof, and belongs to the technical field of vaccine preparation. The vaccine is an artificial synthetic vaccine, has the characteristics of easy preparation, small toxicity, low cost, high titer, broad spectrum and conservation, and solves the complicated process of obtaining a vaccine by amplification transformation in the prior art, and improves the preparation efficiency and application efficiency. A combined polypeptide vaccine component having immunoprotection for multiple subtypes of influenza viruses and coronaviruses is designed for influenza viruses and novel coronaviruses, and Montanide ISA51 is used as an adjuvant. After mice immunized with the vaccine are infected with influenza viruses by nose dropping, it is shown that the vaccine immunization has a protective effect on mice adapted strains of influenza A H1N1 and H7N9 viruses, the combined vaccine composed of the screened six polypeptides has a protective effect on multiple influenza viruses, and has the potential to resist coronaviruses.

The invention provides a composite vaccine adjuvant based on ergothioneine-sulfhydrylated polypeptide and a vaccine composition and application thereof, and belongs to the crossing field of biotechnology and medicine (including veterinary use). The composite vaccine adjuvant comprises a component A and a component B, wherein the component A comprises the following components in percentage by weight: 0.5%-5.0% of L-ergothioneine, 0.3%-2.0% of (Gly-SH) n oligopeptide, 2.0%-8.0% of aluminum hydroxide and / or aluminum phosphate, 1.0%-3.0% of a targeting carrier, 5.5%-13.0% of a freeze-drying protective additive and the balance of a buffer solution; the component B is CpG ODN, and the final concentration of the component B is 10-25 mu g / mL. The composite vaccine adjuvant system integrates sulfhydrylation modification enhanced combination and multi-component synergistic immunization, can be used for inducing balanced Th1 / Th2 immune response of mammals (including human, pigs, cattle and the like) and birds (chicken, ducks and the like) to intracellular / extracellular pathogens, and can be adapted to subunit vaccines, inactivated vaccines, recombinant antigen vaccines and combined vaccines; meanwhile, healthy groups and immunosuppressive groups (young, stress substance and immunodeficient groups) are compatible.

The invention relates to the technical field of veterinary biological products, in particular to a preparation method of a mixed vaccine for combined immunization of foot-and-mouth disease and other pig live vaccines and an immunization method. The preparation method of the mixed vaccine for combined immunization of the foot-and-mouth disease and other pig live vaccines comprises the following steps: heating the foot-and-mouth disease inactivated vaccine to 20-25 DEG C, using the foot-and-mouth disease inactivated vaccine as a dilution matrix, dissolving the pig live vaccines needing combined immunization, and uniformly mixing to form a stable emulsion, thereby obtaining the mixed vaccine. According to the mixed vaccine disclosed by the invention, the immunological injection times are reduced, and the stress and cross infection risks of pigs are reduced; it is ensured that the titer of antibodies corresponding to all vaccines after combined immunization reaches the protection standard, and the immunization effect is better than that of independent immunization or simple mixed immunization; the method is simple to operate, low in cost and suitable for popularization and application in the aspect of enhancing immunity in large-scale pig farms.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a combined vaccine of a porcine deltacoronavirus antigen. The combined vaccine comprises an antigen and a pharmaceutically acceptable carrier, the antigen comprises an immune effective dose of porcine deltacoronavirus PDCoV HN02 or a culture thereof, the porcine deltacoronavirus PDCoV HN02 is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: V202441, the preservation address is Wuhan University, Wuhan, China, and the preservation date is March 28, 2024. The invention also relates to an application of the porcine delta coronavirus PDCoV HN02 or the culture of the porcine delta coronavirus PDCoV HN02 in a combined vaccine. After pigs are immunized by the combined vaccine, clinical symptoms caused by mixed infection can be relieved, and effective protection is provided for the pigs.

The application discloses a combined vaccine for preventing hand-foot-mouth disease, which comprises inactivated enterovirus 71 virus, and inactivated coxsackievirus A 16 virus, coxsackievirus A 10 virus and coxsackievirus A 6 virus. The application also discloses a method for preparing the combined vaccine, and the prepared vaccine has good adsorption effect and stability. The multiple antigens do not interfere with antigenicity and immunization effect of each other after immunizing an object, and have good immunogenicity and safety. The use of the combined vaccine can obviously simplify a vaccine inoculation procedure, improve inoculation efficiency and reduce cost.

The invention relates to a HPV vaccine composition and a dengue vaccine composition for use in a method of preventing an HPV-associated disease and dengue disease in a subject or in a subject population, the method comprising concomitantly administering the HPV vaccine composition and the dengue vaccine composition, wherein the dengue vaccine composition is a tetravalent dengue composition comprising live, attenuated DENV-1, DENV-2, DENV-3 and DENV-4 strains and wherein the method provides combined vaccine efficacy against all four serotypes of the dengue virus and non-inferiority of the immune respone to the HPV vaccine composition compared to a mono-administratrion of the HPV vaccine composition.

The application provides a monoclonal antibody 4E3 and a monoclonal antibody 4D5 which specifically bind to a SEA type O foot-and-mouth disease virus, and a double-antibody sandwich kit with the monoclonal antibody 4E3 as a coating antibody and the monoclonal antibody 4D5 as an enzyme-labeled antibody; the kit can quantitatively detect the content of the SEA type O foot-and-mouth disease virus-like particles, and can detect the content of the SEA type O foot-and-mouth disease virus-like particles in a single vaccine, a multivalent vaccine or a combined vaccine; and can quantitatively detect the content of antigens in a semi-finished vaccine or a finished vaccine.

The application discloses a tumor antigen for glioma and application thereof, and belongs to the field of biomedical technology. Based on a novel curative effect marker URGCP, HEATR1 and HCMV screening and verification, effective immunogenic peptide segments are obtained, a trivalent vaccine is prepared, and the trivalent vaccine is verified to enhance the antigen presentation ability of DCs in vitro. After overexpression of HCMV and exploration of a suitable radiation dose, in-vivo experiments are used to verify that the trivalent mixed vaccine promotes DC homing, lymph node activation, tumor-specific T cell generation, establishment of humoral immunity and memory immunity. Finally, a preventive model and a therapeutic model are used to verify that the universal DC vaccine can inhibit tumor progression and has good safety.